\
&
Contact us
\
&
Contact us
Published on | 1 month ago
ProgrammesThe Empowering Women in Agrifood (EWA) Advance Programme is designed to support advanced-stage women-led ventures in the agrifood sector. The programme aims to enhance participants' commercial and investment readiness, with applications open until 26 April 2026.
It will run from September to December 2026, offering tailored support including expert training, one-to-one mentoring, networking, and connections to investors and corporations. Up to ten selected entrepreneurs will engage in structured sessions that cover commercial strategy, investment readiness, and scaling.
Participants will also have the chance to present their businesses at a final Demo Day, where winners could receive prizes of up to 20.000 EUR to further enhance their growth.
This information is relevant to female entrepreneurs in the agrifood sector, particularly those looking to scale their startups. Additional details can be found on the EIT Food website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
